Cardiovascular diseases are major contributors to morbidity and mortality and pose a huge burden to the health care system. Thrombosis is the most common etiology for ischemic heart disease, ischemic stroke, and venous thromboembolism. 
United States showed that 28% of venous thromboembolism-affected patients experienced bleeding within 1 year after diagnosis, with half of the episodes being a major bleeding event.
2 Even though direct-acting oral anticoagulants are safer with regard to major, fatal, and intracranial bleeding than vitamin K antagonists, 3 the annual rates of major bleeding in clinical practice are still as high as 3% to 4%, as found in a prospective
German study of patients who were treated with rivaroxaban. 4 Hence, although they are extremely effective, the safety of the 
